Pallas Capital Advisors LLC Makes New $514,000 Investment in Sarepta Therapeutics, Inc. $SRPT

Pallas Capital Advisors LLC acquired a new stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 23,896 shares of the biotechnology company’s stock, valued at approximately $514,000.

A number of other institutional investors have also recently made changes to their positions in SRPT. Vanguard Group Inc. increased its holdings in shares of Sarepta Therapeutics by 18.1% in the third quarter. Vanguard Group Inc. now owns 10,817,446 shares of the biotechnology company’s stock worth $208,452,000 after purchasing an additional 1,657,267 shares during the last quarter. Erste Asset Management GmbH boosted its stake in Sarepta Therapeutics by 65.7% during the third quarter. Erste Asset Management GmbH now owns 2,685,945 shares of the biotechnology company’s stock valued at $50,588,000 after buying an additional 1,064,530 shares during the last quarter. Aberdeen Group plc grew its holdings in Sarepta Therapeutics by 59.6% during the 3rd quarter. Aberdeen Group plc now owns 1,982,764 shares of the biotechnology company’s stock valued at $38,208,000 after buying an additional 740,360 shares in the last quarter. First Trust Advisors LP grew its holdings in Sarepta Therapeutics by 209.1% during the 3rd quarter. First Trust Advisors LP now owns 1,939,781 shares of the biotechnology company’s stock valued at $37,380,000 after buying an additional 1,312,220 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in Sarepta Therapeutics by 183.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,745,051 shares of the biotechnology company’s stock worth $33,627,000 after acquiring an additional 1,129,610 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total transaction of $123,207.78. Following the transaction, the director owned 1,765 shares in the company, valued at $30,040.30. The trade was a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 7.60% of the stock is owned by insiders.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT opened at $21.76 on Wednesday. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -2.58, a PEG ratio of 0.31 and a beta of 0.42. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.32 and a quick ratio of 1.48. The business has a 50 day simple moving average of $18.69 and a 200-day simple moving average of $20.08. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $67.47.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The company had revenue of $442.93 million for the quarter, compared to the consensus estimate of $390.95 million. During the same period in the prior year, the firm posted $1.90 EPS. The business’s revenue for the quarter was down 32.7% compared to the same quarter last year. Equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Analyst Ratings Changes

SRPT has been the topic of several recent research reports. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta Therapeutics in a report on Monday, March 2nd. Oppenheimer restated an “outperform” rating and issued a $37.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, March 19th. Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a research note on Thursday, March 26th. Loop Capital set a $25.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 3rd. Finally, Wall Street Zen upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Nine research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $32.30.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.